JP2005520809A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520809A5
JP2005520809A5 JP2003560041A JP2003560041A JP2005520809A5 JP 2005520809 A5 JP2005520809 A5 JP 2005520809A5 JP 2003560041 A JP2003560041 A JP 2003560041A JP 2003560041 A JP2003560041 A JP 2003560041A JP 2005520809 A5 JP2005520809 A5 JP 2005520809A5
Authority
JP
Japan
Prior art keywords
salt
composition
salt according
manufacture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003560041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005520809A (ja
JP4384495B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/000515 external-priority patent/WO2003059939A1/en
Publication of JP2005520809A publication Critical patent/JP2005520809A/ja
Publication of JP2005520809A5 publication Critical patent/JP2005520809A5/ja
Application granted granted Critical
Publication of JP4384495B2 publication Critical patent/JP4384495B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003560041A 2002-01-16 2003-01-15 固体のベンズアゼピン化合物の塩および医薬化合物の調製におけるそれらの使用 Expired - Lifetime JP4384495B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075621 2002-01-16
NL1019762 2002-01-17
PCT/EP2003/000515 WO2003059939A1 (en) 2002-01-16 2003-01-15 Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds

Publications (3)

Publication Number Publication Date
JP2005520809A JP2005520809A (ja) 2005-07-14
JP2005520809A5 true JP2005520809A5 (US20040106767A1-20040603-C00005.png) 2006-01-19
JP4384495B2 JP4384495B2 (ja) 2009-12-16

Family

ID=26077601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003560041A Expired - Lifetime JP4384495B2 (ja) 2002-01-16 2003-01-15 固体のベンズアゼピン化合物の塩および医薬化合物の調製におけるそれらの使用

Country Status (16)

Country Link
US (1) US6998398B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP1468010A1 (US20040106767A1-20040603-C00005.png)
JP (1) JP4384495B2 (US20040106767A1-20040603-C00005.png)
KR (1) KR100979077B1 (US20040106767A1-20040603-C00005.png)
CN (1) CN100591689C (US20040106767A1-20040603-C00005.png)
AU (1) AU2003206755B2 (US20040106767A1-20040603-C00005.png)
BR (1) BR0306701A (US20040106767A1-20040603-C00005.png)
CA (1) CA2473447A1 (US20040106767A1-20040603-C00005.png)
HK (1) HK1072946A1 (US20040106767A1-20040603-C00005.png)
HR (1) HRP20040560A2 (US20040106767A1-20040603-C00005.png)
IL (1) IL162645A0 (US20040106767A1-20040603-C00005.png)
MX (1) MXPA04006887A (US20040106767A1-20040603-C00005.png)
NO (1) NO330528B1 (US20040106767A1-20040603-C00005.png)
PL (1) PL371511A1 (US20040106767A1-20040603-C00005.png)
RU (1) RU2303041C2 (US20040106767A1-20040603-C00005.png)
WO (1) WO2003059939A1 (US20040106767A1-20040603-C00005.png)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050009031A (ko) * 2003-07-15 2005-01-24 엘지전자 주식회사 1회 기록 가능한 광디스크 및 광디스크의 관리정보 기록방법
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
JP4824573B2 (ja) 2003-11-18 2011-11-30 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腎不全、腎疾患または腎障害、特に糖尿病患者におけるこれらの治療のための医薬組成物
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
PL424452A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Similar Documents

Publication Publication Date Title
JP2008514611A5 (US20040106767A1-20040603-C00005.png)
JP2009504763A5 (US20040106767A1-20040603-C00005.png)
JP2008505157A5 (US20040106767A1-20040603-C00005.png)
JP2010500343A5 (US20040106767A1-20040603-C00005.png)
JP2011519910A5 (US20040106767A1-20040603-C00005.png)
CA2632626C (en) Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
JP2006500394A5 (US20040106767A1-20040603-C00005.png)
EP1862458A3 (en) Therapeutic agents useful for treating pain
JP2006182786A5 (US20040106767A1-20040603-C00005.png)
JP2005520809A5 (US20040106767A1-20040603-C00005.png)
JP2010077141A5 (US20040106767A1-20040603-C00005.png)
JP2009143956A5 (US20040106767A1-20040603-C00005.png)
RU98123589A (ru) Композиция для орального введения, способ снижения обжигающего послевкусия композиций пропионовой кислоты
JP2004536811A5 (US20040106767A1-20040603-C00005.png)
JP2008501000A5 (US20040106767A1-20040603-C00005.png)
JP2005526011A5 (US20040106767A1-20040603-C00005.png)
JP2005520923A5 (US20040106767A1-20040603-C00005.png)
JP2003509349A5 (US20040106767A1-20040603-C00005.png)
EP1712548A3 (en) 5-amino-4-hydroxy-7-(pyridinylmethyl)-alkanamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
JP2008542386A5 (US20040106767A1-20040603-C00005.png)
EP2308828A3 (en) CaSR antagonist
JP2010090149A5 (US20040106767A1-20040603-C00005.png)
JP2010526827A5 (US20040106767A1-20040603-C00005.png)
JP2014505017A5 (US20040106767A1-20040603-C00005.png)
JP2005530852A5 (US20040106767A1-20040603-C00005.png)